Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells.
In recent years, the medical community has witnessed a growing interest in the use of adoptive immunotherapy in patients with malignant lesions refractory to standard treatments. Systemic administration of interleukin 2, in combination with the adoptive transfer of a patient's own activated immune cells, has resulted in objective regression of several types of advanced cancers. Pronounced regression of tumor has also been observed with use of systemic interleukin 2 alone. This ability to augment the immune defense system of the host against cancer has stimulated intense clinical and laboratory investigations.
van Haelst-Pisani
C M
CM
Department of Oncology, Mayo Clinic, Rochester, MN 55905.
Pisani
R J
RJ
Kovach
J S
JS
D000818:Animals; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology*; D008222:Lymphokines; D009369:Neoplasms / Q000628:therapy*
D007376:Interleukin-2; D008222:Lymphokines